ERBB2 and breast carcinoma: We reported the establishment and characterization of a novel breast cancer cell line, named DHSF-BR16, derived from an ER−/PR−/HER2+ primary invasive ductal breast carcinoma of a female patient, still alive and disease-free 5 years from adjuvant chemotherapy.